Phase 2 Bladder Cancer Trial, Recruiting NCT07421700 Sponsor: Pfizer Condition: Bladder Cancer
Back to Bladder Cancer

Phase 2 Bladder Cancer Trial, Recruiting

NCT07421700
Recruiting Phase 2 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years old or older at the time of screening.
  • You must have been diagnosed with advanced or spreading bladder/urinary tract cancer that has been confirmed by a tissue sample (biopsy).
  • Your cancer must be measurable on scans using standard medical guidelines.
  • You must be generally well enough to carry out daily activities with little or no limitation (confirm with trial site for exact fitness level required).
  • Your blood, liver, and kidney test results must be within acceptable ranges.
  • You must be willing to follow the study procedures and sign a consent form agreeing to take part.
  • If you are able to become pregnant, you must agree to use effective birth control during the study and for a set period of time after your last dose.

Who may not be able to join:

  • You may not be eligible if you have had another type of cancer in the past 3 years, or if there are still signs of a previous cancer in your body.
  • You may not be eligible if you have active cancer that has spread to your brain or spinal cord.
  • You may not be eligible if you have an autoimmune disease (where your immune system attacks your own body) that has needed treatment in the past 2 years.
  • You may not be eligible if you have taken part in another clinical trial within the last 30 days or within a certain timeframe related to the previous trial medication (confirm with trial site).
  • You may not be eligible if you are currently pregnant or breastfeeding.
  • You may not be eligible if you are unable or unwilling to follow the study's requirements.
  • You may not be eligible if you or a close family member works directly on this clinical trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Australian sites

Macquarie University, North Ryde, New South Wales
Icon Cancer Centre Wesley, Auchenflower, Queensland
Monash Health, Clayton, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
11 March 2026
Est. completion
6 December 2027

Where this trial is recruiting

🇦🇺 Australia 🇨🇳 China 🇯🇵 Japan Puerto Rico 🇪🇸 Spain 🇺🇸 United States

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Confirmed Objective Response Rate (ORR) by investigator; Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs); Number of participants with dose limiting toxicity (DLT) in Part 1 of Cohort B

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov